Nitoman (Tetrabenazine)

Tetrabenazine, the active ingredient in Nitoman, is a VMAT2 inhibitor presented as an oral tablet for oral use. It is employed in the management of movement disorders such as Huntington’s disease chorea and tardive dyskinesia, targeting patients who require reduction of involuntary movements. The drug reduces dopamine and other monoamines in presynaptic neurons, helping to control excessive motor activity.

GNH USA supplies Nitoman as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Nitoman is a VMAT2 inhibitor used to treat hyperkinetic movement disorders. - Huntington’s disease chorea: reduces the severity and frequency of involuntary movements. - Tardive dyskinesia: alleviates persistent choreiform movements caused by long‑term antipsychotic therapy. - Other hyperkinetic movement disorders: may help control involuntary movements in various neurological conditions.

Adverse reactions may occur with Nitoman use.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach often accompanied by vomiting. - Depression: low mood that may worsen existing depressive symptoms. - Sedation: drowsiness affecting daily activities. - Weight loss: unintended reduction in body weight. - Parkinsonism: stiffness or slowed movements resembling Parkinson disease.

Serious or Rare Side Effects: - Suicidal ideation: thoughts of self‑harm requiring immediate evaluation. - Severe depression: marked mood disturbance that may need psychiatric intervention. - QT interval prolongation: cardiac rhythm changes that can lead to arrhythmia. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.

Before initiating Nitoman, several safety considerations are recommended. - Assess baseline mood: monitor patients for worsening depression or suicidal thoughts. - Evaluate liver function: avoid use in severe hepatic impairment and monitor enzymes regularly. - Check cardiac status: contraindicated in patients with known QT prolongation or significant arrhythmias. - Use caution in the elderly: increased risk of falls and sedation. - Avoid concomitant MAO inhibitors: risk of hypertensive crisis. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nitoman may interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - MAO inhibitors: can cause hypertensive crisis when combined. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase tetrabenazine plasma levels, raising toxicity risk. - Strong CYP2D6 inducers (e.g., rifampin): reduce efficacy by lowering drug concentrations.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure‑lowering effect may require dose adjustment. - Other dopamine‑depleting medications: may enhance motor side effects. - QT‑prolonging drugs (e.g., certain antiarrhythmics): monitor ECG for interval changes.